Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

• Status: Completed
• Trial end date: 2017-12-04
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to determine the incremental intraocular pressure (IOP) lowering that is achieved when Simbrinza is used adjunctively to Travatan in patients with normal tension glaucoma that may benefit from further IOP lowering.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Brimonidine Tartrate; Brinzolamide; Ophthalmic Solutions; Travoprost

Criteria

Inclusion Criteria:

• Sign written informed consent

• Diagnosed with normal tension glaucoma

• Intraocular pressure measurements in at least 1 eye as specified in the protocol

• Willing and able to attend all study visits

Exclusion Criteria:

• History of hypersensitivity to any of the study drugs

• Use of medications prohibited by the protocol

• Pregnant or nursing

• Of child-bearing potential unless using contraception, as specified in the protocol

• Any form of glaucoma other than open angle glaucoma in either eye

• Chronic, recurrent or severe inflammatory eye disease

• Ocular trauma or surgery within the past 6 months in either eye; ocular infection or laser surgery within the past 3 months in either eye (all from screening)

• Conditions which would make the patient, in the opinion of the Investigator, unsuitable for the study.